Publish in this journal
Journal Information
Vol. 70. Issue 12.
Pages 1083-1097 (December 2017)
Visits
Not available
Vol. 70. Issue 12.
Pages 1083-1097 (December 2017)
Special article
Full text access
Spanish Pacemaker Registry. 14th Official Report of the Spanish Society of Cardiology Working Group on Cardiac Pacing (2016)
Registro Español de Marcapasos. XIV Informe Oficial de la Sección de Estimulación Cardiaca de la Sociedad Española de Cardiología (2016)
Visits
11517
Óscar Cano Péreza,b,
Corresponding author
cano_osc@gva.es

Corresponding author: Hospital Universitari i Politècnic La Fe, Área de Enfermedades Cardiovasculares, Planta 4-Torre F, Avda. Fernando Abril Martorell 106, 46026 Valencia, Spain.
, Marta Pombo Jiméneza,c, María Luisa Fidalgo Andrésa,d, Diego Lorente Carreñoa,e, Raúl Coma Samartína,f
a Sección de Estimulación Cardiaca, Sociedad Española de Cardiología, Madrid, Spain
b Unidad de Electrofisiología y Arritmias, Hospital Universitari i Politècnic La Fe, Valencia, Spain
c Unidad de Estimulación, Agencia Pública Empresarial Sanitaria Costa del Sol, Marbella, Málaga, Spain
d Unidad de Electrofisiología y Arritmias, Hospital Universitario de León, León, Spain
e Servicio de Cardiología, Hospital San Pedro, Logroño, La Rioja, Spain
f Unidad de Cuidados Críticos Cardiológicos, Hospital 12 de Octubre, Madrid, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (18)
Show moreShow less
Tables (1)
Table. Public and Private Hospitals Submitting Data to the Spanish Pacemaker Registry in 2016, Grouped by Autonomous Community
Abstract
Introduction and objectives

This report describes the results of analysis of implanted pacemakers reported to the Spanish Pacemaker Registry.

Methods

The analysis was based on information provided by the European Pacemaker Identification Card.

Results

Information was received from 115 hospitals, with a total of 12 697 cards, representing 32.3% of the estimated activity. Use of conventional and resynchronization pacemakers was 818 and 79 units per million inhabitants, respectively. A total of 200 leadless pacemakers were implanted. The mean age of the patients receiving an implant was 77.8 years, and 52% of devices were implanted in persons older than 80 years. In all, 74.9% were first implants and 23.4% corresponded to generator exchange. Endocardial leads were bipolar, 82.9% with active fixation, and 16.1% had magnetic resonance imaging protection. Most patients received bicameral sequential pacing, although single chamber pacing VVI(R) was used in 26.7% of the patients with sick sinus syndrome and in 23.8% of those with atrioventricular block, despite sinus rhythm.

Conclusions

Total use of pacemaker generators in Spain has increased by 1.6% compared with 2015. Most implanted leads have active fixation and less than 20% have magnetic resonance imaging protection. Age and sex directly influenced pacing mode selection, which could be improved in around 32% of patients.

Keywords:
Permanent cardiac pacing
Pacemaker leads
Biventricular pacing
Registry
Abbreviations:
AVB
CRT
CRT-D
CRT-P
CRT-T
EPPIC
SSS
Resumen
Introducción y objetivos

Se describe el resultado del análisis de los dispositivos de estimulación implantados y remitidos al Registro Español de Marcapasos en 2016.

Métodos

Procesado de la información que aporta la Tarjeta Europea del Paciente Portador de Marcapasos.

Resultados

Se recibió información de 115 centros hospitalarios, con un total de 12.697 tarjetas, el 32,3% de la actividad estimada. El consumo de generadores convencionales y dispositivos de resincronización fue de 818 y 79 unidades por millón habitantes respectivamente. Se implantaron 200 marcapasos sin cables. La media de edad de los pacientes que recibieron un implante fue 77,8 años y un 52% de los dispositivos se implantaron en mayores de 80 años. El 74,9% de los procedimientos fueron primoimplantes y el 23,4%, recambios de generador. Los cables endocavitarios utilizados fueron bipolares, el 82,9% con sistema de fijación activa y el 16,1% compatibles con resonancia magnética. Aunque la estimulación secuencial bicameral sigue siendo mayoritaria, se estimula en modo VVI(R) al 26,7% de los pacientes con enfermedad del nódulo sinusal y el 23,8% de aquellos con bloqueo auriculoventricular pese a estar en ritmo sinusal.

Conclusiones

El consumo total de generadores de marcapasos en España ha aumentado en un 1,6% con respecto a 2015. La mayoría de los cables implantados son de fijación activa y menos del 20% tiene protección para la resonancia magnética. Los factores directamente relacionados con la elección del modo de estimulación son la edad y el sexo. En alrededor del 32% de los casos podría mejorarse la elección del modo de estimulación.

Palabras clave:
Marcapasos
Cables marcapasos
Estimulación biventricular
Registro
Full Text
INTRODUCTION

The official report of the Spanish Pacemaker Registry has been published annually since 1997,1–15 and describes cardiac pacing procedures performed in Spain in the previous year. This report describes real-world clinical practice, the extent to which these procedures are in line with current clinical guidelines, evolving trends in recent years, and compares these pacing procedures with those conducted in other European countries.16 The current report provides information on pacemakers implanted in 2016.

METHODS

The Spanish Pacemaker Registry uses 3 information sources to prepare the annual report: the Spanish National Institute of Statistics (Instituto Nacional de Estadísticas [INE]),17 the European Patient Pacemaker Identification Card (EPPIC), and companies that supply the devices.

European Pacemaker Patient Identification Card

Each year, the participating hospitals submit information on pacemaker implantation to the Spanish Pacemaker Registry. This information is based on the data contained in the EPPIC. Some hospitals send electronic data from their own databases. The implementation of the online application developed in agreement with the Spanish Agency of Medicines and Medical Devices remains pending. This application will allow greater involvement of the implanting hospitals, improved quality of data collection, and a more reliable and representative analysis of cardiac pacing activity in Spain.

Device Suppliers

Current legislation on monitoring possible alerts (Royal Decree 1616/2009, dated 26 October, which regulates all active implantable healthcare devices), requires all implanting hospitals to complete the EPPIC. However, less than 100% of the cards are completed and some hospitals fail to send the EPPIC to the Spanish Pacemaker Registry. Therefore, data on all devices (pacemaker generators and cardiac resynchronization therapy [CRT] devices: high-energy [CRT-D] and low-energy [CRT-P]) implanted in Spain and their distribution by autonomous community is provided by the suppliers each year. The information provided by the suppliers to the Spanish Pacemaker Registry is compared with that reported by the European Confederation of Medical Suppliers Associations (Eucomed).18

Spanish National Institute of Statistics

The population figures used to calculate the national and autonomous community implant rates were obtained from the INE updated report dated July 1, 2016.17

Sample Analyzed

A total of 115 centers (Table) provided 12 697 cards reporting 12 654 implants, which represents 32.3% of the generators used according to the information provided by the suppliers. This sample is considered representative of cardiac pacing activity in Spain in 2016.

Table.

Public and Private Hospitals Submitting Data to the Spanish Pacemaker Registry in 2016, Grouped by Autonomous Community

Andalusia 
Clínica de la Inmaculada 
Complejo Hospitalario de Jaén 
Complejo Hospitalario Virgen de la Macarena 
Hospital Costa del Sol 
Hospital del Servicio Andaluz de Salud de Jerez de la Frontera 
Hospital Infanta Elena 
Hospital Juan Ramón Jiménez 
Hospital Punta de Europa 
Aragon 
Hospital Miguel Servet 
Hospital Royo Villanova 
Canary Islands 
Clínica Quirón 
Hospital de la Candelaria 
Hospital Dr. Negrín 
Hospital Insular 
Hospital Universitario de Canarias 
Cantabria 
Hospital Universitario Marqués de Valdecilla 
Castile and León 
Clínica Campogrande 
Clínica Santa Teresa 
Complejo Hospitalario de León 
Hospital Clínico Universitario de Salamanca 
Hospital Universitario Río Hortega 
Hospital General de Segovia 
Hospital General Virgen de la Concha 
Hospital Nuestra Señora de Sonsoles 
Hospital Nuestra Señora de Regla 
Hospital Universitario de Burgos 
Hospital Universitario de Valladolid 
Hospital Recoletas de Segovia 
Castile-La-Mancha 
Clínica IDC Albacete 
Clínica La Antigua 
Hospital General de Ciudad Real 
Hospital General Virgen de la Luz 
Hospital General y Universitario de Guadalajara 
Hospital Virgen de la Salud 
Catalonia 
Complejo Hospitalario Parc Taulí 
Consorcio Sanitario de Mataró 
Hospital Clínic i Provincial de Barcelona 
Hospital de Tortosa Virgen de la Cinta 
Hospital de Lérida Arnau de Vilanova 
Hospital de Terrassa 
Hospital del Mar 
Hospital del Vendrell 
Hospital Germans Trias i Pujol 
Hospital Joan XXIII de Tarragona 
Hospital Mútua de Terrassa 
Hospital Sant Pau i Santa Tecla 
Extremadura 
Hospital Comarcal de Zafra 
Hospital Comarcal Don Benito-Villanueva 
Galicia 
Clínica Quirón 
Complejo Hospitalario Universitario de A Coruña 
Compolejo Hospitalario Universitario del Ferrol 
Hospital Álvaro Cunqueiro 
Hospital do Meixoeiro 
Hospital Locus Augusti 
Hospital Montecelo 
Hospital San Rafael 
Balearic Islands 
Hospital Mateu Orfila 
Hospital Son Llàtzer 
Hospital Universitario Son Espases 
La Rioja 
Hospital de San Pedro 
Community of Madrid 
Clínica La Paloma 
Clínica Nisa Pardo Aravaca 
Clínica Nuestra Señora de América 
Clínica Quirón 
Clínica Rúber 
Clínica San Camilo 
Clínica La Luz 
Clínica Nuestra Señora del Rosario 
Fundación Hospital Alcorcón 
Fundación Jiménez Díaz 
Hospital 12 de Octubre 
Hospital de Fuenlabrada 
Hospital de Móstoles 
Hospital de Torrejón 
Hospital del Henares 
Hospital General Gregorio Marañón 
Hospital Infanta Leonor 
Hospital La Paz 
Hospital Madrid-Montepríncipe 
Hospital Príncipe de Asturias 
Hospital Puerta del Sur Móstoles 
Hospital Ramón y Cajal 
Hospital San Francisco de Asís 
Hospital San Rafael 
Hospital Sanchinarro 
Hospital Severo Ochoa 
Hospital Universitario de Getafe 
Hospital Universitario Puerta de Hierro 
Hospital Universitario San Carlos 
Region of Murcia 
Clínica La Vega 
Hospital General Santa María del Rosell 
Hospital Morales Meseguer 
Hospital Dr. Rafael Méndez 
Hospital Universitario Virgen de la Arrixaca 
Chartered Community of Navarre 
Clínica Universitaria de Navarra 
Complejo Hospitalario de Navarra 
Hospital de Navarra 
Basque Country 
Hospital de Cruces 
Hospital Universitario de Araba (Txagorritxu) 
Principality of Asturias 
Fundación Hospital de Jove 
Hospital Central de Asturias 
Hospital de Cabueñes 
Valencian Community 
Clínica de Benidorm 
Clínica Vista Hermosa 
Hospital de Sagunto 
Hospital de Vinalopó 
Hospital General de Alicante del SVS 
Hospital General Universitario de Elche 
Hospital IMED de Elche 
Hospital Medimart 
Hospital Perpetuo Socorro 
Hospital Quirón Torrevieja 
Hospital Universitari i Politècnic La Fe 
Hospital Universitario de San Juan de Alicante 
Hospital Vega Baja 
RESULTSQuality of Data Collection

The percentage of missing data for each parameter varied widely, ranging from 2.5% for the polarity of implanted leads to 60.3% for the etiology of the implant. The following percentages were also missing: preimplantation symptoms, 47.9%; sex, 25.7%; age, 8.3%; type of lead fixation, 30.5%; preimplantation electrocardiogram, 42.1%; reason for generator explantation, 17.8%; and reason for lead explantation, 3.8%. The reported percentages were calculated based on the data available for each parameter after the exclusion of missing data.

Number of Pacemaker Generators Implanted

According to data obtained from the Spanish Pacemaker Registry, a total of 12 654 generators were implanted, corresponding to the 115 participating hospitals. According to the information provided by the suppliers, in 2016, 37 990 pacemakers and 1227 CRT-P devices were implanted, forming a total of 39 217 devices. According to Eucomed, 38 086 devices and 1207 CRT-P devices were implanted,18 representing a 1.6% increase compared with the number of devices implanted in 2015.

According to the INE report, as of 1 July, 2016, the Spanish population was 46 468 102 (females, 23 654 467; males, 22 813 635), representing an increase of 45 038 people (0.1%) compared with the population in 2015.17

Based on these population data, the Spanish Pacemaker Registry and Eucomed reported an implantation rate of 818 and 820 units/million population (Figure 1), respectively. These figures are significantly lower than the European average (965 units/million population) and those of Germany, Belgium, Finland, and Italy (more than 1000 units/million population), but are higher than those of countries with higher per capita income, such as the United Kingdom, the Netherlands, Norway, and Switzerland (756, 726, 791, and 815 units/million population, respectively).18

Figure 1.

Total number of pacemaker generators and primary implants per million population, 2007-2016.

(0.18MB).

The autonomous communities with the highest implantation rates were Galicia, the Principality of Asturias, and Castile and León, with more than 1000 units/million population, whereas the lowest rates were found in La Rioja, Extremadura, and the Chartered Community of Navarre (less than 700 units/million population) (Figure 2). The implantation rate in the Region of Murcia was notable, with 825 units/million population, representing an increase of 43% compared with that of the previous year.

Figure 2.

Use of pacemakers per million population (with national mean and by autonomous community), 2012 to 2014.

(0.31MB).
Cardiac Resynchronization Devices

According to the Spanish Pacemaker Registry, the total number of CRT (CRT-T) devices implanted in 2016 was 3679 (79 units/million population), a figure similar to that reported by Eucomed (80 units/million population), which represents an increase of 7.7% compared with that of the previous year (Figure 3). The Spanish Pacemaker Registry reported a CRT-P implantation rate of 26 units/million population, which was exactly the same figure as that reported by Eucomed. This rate was one of the lowest in Europe, and was only higher than those reported for Greece and Poland, with 6 and 18 units/million population, respectively. According to the Spanish Pacemaker Registry and Eucomed, the CRT-D implantation rate was 53 and 54 units/million population, respectively. These rates were the lowest in Europe, which has an average rate of 129 units/million population.

Figure 3.

Number of cardiac resynchronization therapy devices implanted from 2007 to 2016. CRT-D, high-energy biventricular generator; CRT-P, low-energy biventricular generator; CRT-T, total biventricular generators.

(0.19MB).

Cantabria, the Chartered Community of Navarre, the Valencian Community, and Extremadura were the autonomous communities with the highest CRT-T implantation rates, with more than 100 units/million population, followed by the Community of Madrid and the Principality of Asturias, with 92 and 87 units/million population, respectively (Figure 4 and Figure 5). La Rioja was the autonomous community with the lowest implantation rate, with 29 units/million population. As in 2015, Cantabria, the Chartered Community of Navarre, and Extremadura had the highest CRT-P implantation rates, with 77, 56, and 48 units/million population, respectively. The Valencian Community and the Principality of Asturias are noteworthy, with more than 70 units/million population.

Figure 4.

Use of cardiac resynchronization devices per million population (with national mean and by autonomous community) in 2016. CRT-D, high-energy biventricular generator; CRT-P, low-energy biventricular generator; CRT-T, total biventricular generators.

(0.24MB).
Figure 5.

Trends in the use of cardiac resynchronization devices per million population, 2014-2016. CRT-T, total biventricular generators.

(0.28MB).
Age and Sex of the Population

Pacemaker use was still higher in men than in women (58.2% vs 41.8%), both in primary implants (59.0% vs 41.0%) and in generator exchanges (55.7% vs 44.3%).

The mean age of all patients undergoing intervention was 77.8 years (78.9 years for exchanges and 77.6 years for primary implants). The mean age of female patients was slightly higher than that of male patients (78.9 years vs 77.6 years). The highest percentage of implants continued to be in the age-range 80 to 89 years (42.9%), followed by 70 to 79 years (30.8%), 60 to 69 years (11.8%), and 90 to 99 years (8.9%). The lowest percentage of implants was in patients younger than 60 years (< 6%). Patients older than 99 years received 0.2% of implants (Figure 6).

Figure 6.

Distribution of implants by age group.

(0.1MB).
Implantations and Generator and Lead Exchanges

Primary implants comprised 74.9% of all procedures in 2016, with 632 primary implants/million population. Of the remaining procedures, generator exchanges comprised 23.4%, generator and lead exchanges 1.4%, and lead exchanges 0.3%.

The most common reason for generator exchange was battery depletion (87.8%), followed by elective exchange (4.1%), reintervention due to the hemodynamic consequences of pacemaker syndrome (1.8%), early depletion due to elevated thresholds, programmed high-output energy, or battery life less than expected (1.2%), malfunction or recall (1.1%), and unspecified causes (<1%). The generator removal rate due to erosion, infection, or protrusion was higher than that of the previous year (3.4% vs 1.4%).

There were 216 lead explantations. The most common reason was infection or ulceration (65.6%), followed by insulation fracture (7.7%), dislodgement (7.7%), and, less commonly, connection failure (3.8%), extracardiac pacing (3.8%), exit blockage (3.8%), or elective exchange (3.8%). The remainder were explanted due to unspecified causes (3.8%).

Pacing LeadsPolarity

The use of bipolar leads was very high, with the same percentage used in the right atrium as in the right ventricle (99.9%). In line with the upward trend in recent years (34.1% in 2014 and 64.3% in 2015), 95.1% of leads implanted in the coronary sinus for left ventricular pacing were bipolar.

Lead Fixation Systems

Most of the leads used were active fixation leads (82.9%) fitted with retractable helixes allowing their placement in sites other than the apex of the right ventricle and right atrial appendage with a lower risk of dislodgement (Figure 7). Active fixation leads were mainly used in the right atrium (84.1%) and right ventricle (82.2%) and, unlike previous years, the use of active fixation was similar in patients older and younger than 80 years (81.6% and 83.5%, respectively).

Figure 7.

Distribution of active fixation leads implanted in the atrium and ventricle, 2007 to 2016.

(0.2MB).
Compatibility With Magnetic Resonance Imaging

The Spanish Pacemaker Registry reported 1616 leads compatible with magnetic resonance imaging (MRI), representing 16.1% of all implanted leads, with similar use in the right atrium (15.6%) and right ventricle (16.3%). The use of these leads continued to be lower in patients older than 80 years (12.9%) than in those younger than 80 years (17.5%). The information collected in the EPPIC is insufficient to report the percentage of MRI-compatible generators implanted.

Preimplantation Symptoms, Etiology, and ElectrocardiogramSymptoms

The most common preimplantation symptom was syncope (40.4%), followed by dizziness (24.7%), dyspnea (17.5%), and bradycardia (10.3%). Of the patients implanted with a pacemaker, 3.6% were asymptomatic and were fitted with the device with prophylactic intent. Less common symptoms were tachycardia (1.1%), chest pain (1.0%), cerebral dysfunction (0.4%), recovered sudden cardiac arrest (0.3%), and unspecified causes (0.7%).

Etiology

The most common reason for implantation was conduction system fibrosis and unknown etiology (81.9%), followed by ischemic etiology (5%; postinfarction, 0.3%), iatrogenic etiology (4%; postablation, 1.1%), cardiomyopathy (3.1%; hypertrophic cardiomyopathy, 0.4%), valvular heart disease (2.4%), congenital heart disease (0.7%), carotid sinus syndrome (6%), vasovagal syndrome (0.2%) and, as rarer causes, myocarditis and heart transplant (< 0.1%). The remainder (1.9%) corresponded to as yet unspecified or coded etiologies.

Preimplantation Electrocardiogram

The most common electrocardiographic abnormality was atrioventricular block (AVB) (57.5%), comprising third-degree AVB (37.8%), second-degree AVB (13.6%), atrial fibrillation (AF) with complete AVB (4.1%), and first-degree AVB (2.0%) (Figure 8). The second most common electrocardiographic abnormality was sick sinus syndrome (SSS) (31.4%), which included AF with bradycardia (12.9%), bradycardia-tachycardia syndrome (7.2%) and, less commonly, sinus bradycardia (4.9%), unspecified SSS (3.6%), sinus arrhythmia (1.7%), sinoatrial exit block (0.9%), interatrial block (0.1%), and chronotropic incompetence (0.1%). Other reasons for implantation were bundle branch block (5.4%), atrial tachycardia (0.4%), ventricular tachycardia (0.1%), normal sinus rhythm with or without electrophysiological abnormalities (5.1%), and unspecified causes (0.1%).

Figure 8.

Trends in electrocardiographic abnormalities prior to implantation, 2007 to 2016. AF/AFL + BRAD, atrial fibrillation or atrial flutter with bradycardia; AVB, atrioventricular block; ICD, intraventricular conduction defect; SSS, sick sinus syndrome.

(0.19MB).

Regarding sex differences on preimplantation electrocardiogram, AVB was more common in men (55.5% vs 49.2%, excluding blocked AF), followed by blocked AF or AF with bradycardia (17.7% vs 15.5%), and bundle branch block (6.2% vs 3.2%). Sick sinus syndrome (excluding slow AF) was more common in women (25.1% vs 14.8%).

Remote Monitoring/Follow-up

In 2016, there was a significant increase in the use of remote monitoring, involving 4373 pacemakers (11.5% of all implanted pacemakers) and 781 CRT-P devices (65% of all CRT-P devices).

Leadless Pacemakers

For the second consecutive year, data were available on leadless pacemaker implantation. In 2016, 200 leadless pacemaker units were implanted. All these units were supplied by a single manufacturer (Micra Model, Medtronic). The mean age of the patients who underwent implantation of this device was 79.9 ± 10.4 years. Compared with the previous year, there was a significant increase (61%) in implantations of leadless devices. Four more autonomous communities have also begun to perform this type of implant. Only 24 of the 200 implanted units have remote monitoring. Taking these figures into account, leadless pacing accounted for 5.3% of all VVI/R devices implanted in 2016.

Pacing Modes

In 2016, single-chamber pacing comprised 39.8% of all implanted generators (Figure 9). This percentage included single-chamber atrial pacing (AAI/R) (0.4%), which represented a slight decrease compared with that of 2015. The number of primary implants in AAI/R mode significantly decreased compared with those of the previous year (0.3%) as the number of generator exchanges continued to fall (0.8% of all implants). The use of single-chamber ventricular pacing (VVI/R) underwent a slight increase compared with that of the previous year (39.3% of all implanted generators), mainly due to a slight increase in generator exchanges (39.2%), given that the number of primary implants remained almost identical (39.4%). Taking into account the electrocardiographic diagnosis prior to implantation, with only 7.4% of implants being performed in patients with permanent atrial tachyarrhythmia, an estimated 32% of the patients who received single-chamber ventricular pacing may have received a pacemaker capable of maintaining AV synchrony. However, the final decision on the choice of pacing mode can be affected by several factors, which are discussed in the section on pacing mode selection.

Figure 9.

Trends in pacing modes, 2007 to 2016. AAI/R, single-chamber atrial pacing; DDD/R, sequential pacing with 2 leads; VDD/R, single-lead sequential pacing; VVI/R, single-chamber ventricular pacing.

(0.18MB).

One- or 2-lead dual-chamber sequential pacing comprised 57.3% of all implanted generators. This percentage remained stable compared with that of previous years. Single-lead sequential pacing (VDD/R) was used in 10.2% of all implanted units, representing a slight increase compared with its use in the previous year (Figure 9). The gradual decrease in primary implants and generator exchanges in recent years was followed by a slight increase (8.9% in primary implants and 14% in exchanges). The most commonly used mode was 2-lead dual-chamber pacing (DDD/R) (47.2% of all implanted generators, 48.7% of primary implants, and 42.4% of exchanges) (Figure 9). The use of DDD/R devices fitted with biosensors that allow the pacing frequency to be varied has almost become standard practice (94.3% of all devices).

There was a continued upward trend in the use of biventricular pacing for CRT, both in defibrillator-associated mode and pacemaker-associated mode. In 2016, a total of 1227 CRT-P devices were implanted, representing an increase of 145 units compared with those implanted in 2015 (13.4%; 26 units/million population). In Spain, the use of CRT-P comprised 32.7% of all CRT devices implanted.

Pacing Mode SelectionAtrioventricular Block

To assess the appropriate use of the most widely recommended pacing modes, this report was limited to patients in sinus rhythm, excluding patients with permanent atrial tachyarrhythmia with AVB (EPPIC code C8). We analyzed possible factors that could have influenced selection, such as patient age, sex, and degree of block.

The most commonly used pacing mode was atrial synchronous pacing (DDD/R and VDD/R modes) (74.9%), a percentage that was similar to that of previous years (Figure 10). The use of DDD/R mode (60.6%) and VDD/R mode (14.3%) remained stable. Similarly, the use of VVI/R mode barely changed compared with data from the previous year (23.8%).

Figure 10.

Trends in atrioventricular block pacing modes, 2007 to 2016. DDD/R, sequential pacing with 2 leads; VDD/R, single-lead sequential pacing; VVI/R, single-chamber ventricular pacing.

(0.17MB).

Age continued to influence the choice of pacing mode. In patients aged 80 years or younger, the use of pacing with preserved AV synchrony was clearly in the majority (86.9% of patients), with DDD/R being the most commonly used mode (75.1%). In this age group, DDD/R was the most commonly used mode, while the use of VDD/R mode (11.8%) slightly increased compared with its use in the previous year (Figure 11). In contrast, in patients older than 80 years, there was a significant decrease of pacing with preserved AV synchrony to 61.5%, and there was a slight decrease in single-chamber ventricular pacing to 37.8%, which was a slightly lower percentage than that of the previous year (Figure 12). The VDD/R mode was used more in patients older than 80 years than in younger patients, whereas DDD/R mode was used more in both age groups (19.5% vs 42%) (Figure 11).

Figure 11.

Trends in single-lead sequential pacing in atrioventricular block by age group (≤ 80 or > 80 years), 2007 to 2016. VDD/R, single-lead sequential pacing.

(0.16MB).
Figure 12.

Trends in single-chamber ventricular pacing in atrioventricular block by age (cut-off point at 80 years). VVI/R, single-chamber ventricular pacing.

(0.16MB).

Atrial-based pacing was analyzed according to the degree of AVB. This modality was more commonly used in patients with first- or second-degree AVB (77%) than in patients with third-degree AVB (72.6%). These differences were due to the greater use of DDD/R mode in patients with first- and second-degree AVB, a trend that has been observed in recent years. However, these differences were minimal in patients aged 80 years or younger (87.9% in first- or second-degree AVB vs 85.6% in third-degree AVB), whereas they were slightly more pronounced in those older than 80 years (64.3% in first- or second-degree AVB vs 58.1% in third-degree AVB).

As in previous years, there were sex-associated differences in the choice of pacing mode.11–14 The DDD/R pacing was used more often in men, whereas VDD/R pacing was used slightly more often in women. In women aged 80 years or younger, the use of DDD/R mode was still lower than its use in men, as was the case in previous years (72.3% vs 77.5%, respectively), due to the more frequent use of VDD/R mode in women than in men (14% vs 11%) and VVI/R mode (12.3% vs 9.6%). Overall, sequential pacing was used 2.4% less in women aged 80 years or younger and 4.2% less in women older than 80 years than in the equivalent male groups.

In the setting of an electrocardiographic diagnosis of AVB with preserved sinus rhythm, there continues to be a high percentage of patients who receive single-chamber VVI/R pacing. This pacing mode comprised 23.8% of the total (Figure 10). Its use was marked in the oldest patients (37.8% of those older than 80 years) (Figure 12), and its use was greater in patients with third-degree block and in women from both age groups.

Intraventricular Conduction Disorders

In this group of patients, dual-chamber DDD/R pacing remains the most widely used mode (52.4% of implants), although there has been a slight decrease due to the slight increase in the use of VVI/R (29.2%) and VDD/R (8.6%) (Figure 13). In general, the most commonly used devices were AV synchronous pacemakers (69.8% of all implants), a percentage slightly lower than that of previous years.

Figure 13.

Trends in pacing modes in intraventricular conduction defect, 2007 to 2016. DDD/R, sequential pacing with 2 leads; VDD/R, single-lead sequential pacing; VVI/R, single-chamber ventricular pacing.

(0.19MB).

The pacing mode in this subgroup of patients was again influenced by patient age, as was the case in patients with AVB. VVI/R pacing was much more common in patients older than 80 years (47.5% of implants) and for the first time exceeded the percentage of DDD/R devices implanted in patients in this age group (35.7%). In contrast, in patients aged 80 years or younger, VVI/R mode was used in only 16.3%, and DDD/R was the most widely used mode (63.6%). VDD/R mode was more frequently used in patients older 80 years than in younger patients (11.2% vs 6.7%).

The implantation of CRT-P devices was much more common (12.9% of implants) in patients younger than 80 years (5.6%).

Sick Sinus Syndrome

The appropriateness of pacing modes according to current recommendations of clinical practice guidelines19,20 was assessed by dividing the patients into 2 large groups. One group comprised patients who were theoretically in atrial fibrillation or flutter with permanent bradycardia or associated bradycardia (EPPIC code E6), and the other group comprised patients who, at least theoretically, remained in sinus rhythm.

  • A.

    Sick sinus syndrome in permanent atrial tachyarrhythmia, As expected in this situation, most implanted generators were VVI/R (93.6%). However, 4.8% received a DDD/R generator and, as in previous years, 0.3% still received a VDD/R device, which is difficult to justify in SSS. The use of DDD/R mode could be explained in patients who are expected to recover sinus rhythm. A CRT-P device was used in 1.3% of patients. This percentage was more than twice the number of CRT-P implants performed in this setting in the previous year.

  • B.

    Sick sinus syndrome in sinus rhythm, In the remaining electrocardiographic manifestations of SSS, the predominant rhythm was sinus rhythm, either stable or intermittent. The most commonly used pacing mode continued to be DDD/R (69.1%), as recommended by current clinical practice guidelines, followed by VVI/R (26.7%), AAI/R (2.3%), and VDD/R (1%) (Figure 14). Compared with the percentages reported for the previous year, the use of AAI/R mode decreased slightly and remained very low. This decrease may have been due to increased compliance with the recommendations of the latest clinical practice guidelines published in 2013.19 There was a slight increase in the percentage of patients with VDD/R pacing compared with the previous year. The use of VDD/R mode in SSS continued to be anecdotal, which is also appropriate in relation with the recommendations of the clinical practice guidelines, because this pacing mode is not appropriate in SSS, unless there are other circumstances, such as technical difficulties for the implantation of the atrial lead.

    Figure 14.

    Trends in pacing modes in sick sinus syndrome, 2007 to 2016 (excluding EPPIC code E6; chronic atrial fibrillation and bradycardia). AAI/R, single-chamber atrial pacing; DDD/R, sequential pacing with 2 leads; VDD/R, single-lead sequential pacing; VVI/R, single-chamber ventricular pacing.

    (0.19MB).

The various electrocardiographic manifestations of SSS were analyzed, excluding EPPIC subgroups E7 and E8 (interatrial block and chronotropic incompetence), due to their minimal representation over the years. The percentage of VVI/R pacing ranged from 20.4% to 33.3%; once again, the highest percentage corresponded to bradycardia-tachycardia syndrome (EPPIC subgroup E5) (Figure 15). However, these percentages may have been inflated due to the erroneous inclusion of patients with permanent AF with slow-fast episodes in group E5 rather than in group E6 mentioned above.

Figure 15.

Distribution of VVI/R, according to the codes established in the European Pacemaker Patient Identification Card in SSS. E1, unspecified sick sinus syndrome; E2, exit block; E3, sinoatrial arrest; E4, bradycardia; E5, bradycardia-tachycardia syndrome; SSS, sick sinus syndrome; VVI/R, single-chamber ventricular pacing.

(0.11MB).

As was the case in AVB, age continued to influence pacing mode selection in SSS. In patients aged 80 years or younger, there was more frequent use of pacing modes that enable sensing and pacing in the atrium, that is, AAI/R and DDD/R (1.6% and 79.7%, respectively), compared with just 16.5% in VVI/R mode (Figure 16 and Figure 17). However, in patients older than 80 years, VVI/R mode (39% vs 57.2% DDD/R and 1.5% AAI/R) was used much more frequently (Figure 16 and figure 17). These figures are consistent with those obtained in recent years. VDD/R mode was little used in both age ranges (0.9% and 1.5%), although these percentages were slightly greater than those of the previous year (Figure 16). Age was shown to be a factor influencing pacing mode selection over the years studied (Figure 17 and Figure 18).

Figure 16.

Pacing modes in sick sinus syndrome by age (cutoff point at 80 years). AAI/R, single- chamber pacing; E6, chronic atrial fibrillation and bradycardia; DDD/R, sequential pacing with 2 leads; SSS, sick sinus syndrome; VDD/R, single-lead sequential pacing; VVI/R, single-chamber ventricular pacing.

(0.1MB).
Figure 17.

Single-chamber ventricular pacing in patients with sick sinus syndrome, 2007-2016. VVI/R, single-chamber ventricular pacing.

(0.12MB).
Figure 18.

Dual-chamber sequential pacing in sick sinus syndrome by age group (cut-off point at 80 years), 2007-2016. DDD/R, dual-chamber sequential pacing.

(0.16MB).

The influence of sex on pacing mode selection was analyzed. In contrast to previous years, it is noteworthy that in patients older than 80 years, VVI/R mode was used 13.2% more in women than in the men. However, in patients aged 80 years or younger, VVI/R mode was used much less and with very similar percentages in both sexes (16.2% in men vs 15.4% in women).

DISCUSSION

The EPPIC remains the primary source of information submitted to the Spanish Pacemaker Registry. This information was provided by just 115 implantation centers and there was variation in the amount of information completed on each patient card. Although this information can be considered representative of cardiac pacing activity in Spain, the quality of data collection should be improved to obtain a more reliable account of the different aspects of pacing in Spain. We believe that this improvement can be achieved by the implementation of the online application and its widespread use in the implantation centers.

The total use of pacemaker generators in Spain, including CRT-P devices, slightly increased (1.6%) compared with 2015, although this change was less marked than that between 2015 and 2014 (5%). This increase was due to the use of CRT-P devices, which increased by 13.4%, whereas the number of conventional pacemaker generators remained almost the same as that of the previous year. In fact, despite the slight increase in the population, there was a slight decrease in the implantation rate (818 units/million population), breaking the upward trend of recent years. Despite the gradual economic recovery taking place in Spain, it continues to be among the European countries with the lowest rate of pacemaker implantations per million population. The real causes of this low implant rate are unknown, but it is probably influenced by factors other than economics, because countries such as the United Kingdom, the Netherlands, Norway, and Switzerland, with higher per capita income, have a lower implant rate than that of Spain. Other causes may be the lack of training programs and human and material resources, indications not in accordance with clinical guidelines, or health centers with few referral units (arrhythmia and heart failure units).

The number of CRT-T devices increased by 7.7% compared with 2015 (7 units/million population), with a higher increase in the number of CRT-P devices (13.4%) than of CRT-D devices (5.1%). The CRT-D/CRT-P ratio was 2:1 (53:26 units/million population). Despite the above-mentioned increase, the number of units implanted in Spain remains below the European average of the 18 countries reporting their data to Eucomed (mean CRT-P and CRT-D, 48 and 129 units/million population, respectively).

Regarding autonomous communities, the Principality of Asturias, Galicia, and Castile and León implanted the most pacemakers, with more than 1000 units/million population, whereas communities such as the Chartered Community of Navarre, Cantabria, and Extremadura implanted more CRT-P devices, with more than 40 units/million population. In the Region of Murcia, there has been a marked increase in the rate of conventional pacemaker implants (from 576 to 825 units/million population) and CRT-P implants (from 18 to 32 units/million population). Factors that could influence the different implant rates between autonomous communities include differences in the age of the population, economic management, health structure, and the availability of arrhythmia and heart failure units, with consequent differences in the rates for patient referral for implantation.

As in previous years, there was a higher percentage of primary implants and exchanges in men (58.2%). Just over half of implants (52%) are performed in patients older than 80 years.

The most common electrocardiographic abnormality prior to implantation was AVB (57.5%), including second- and third-degree AVB (51.4%), SSS (18.5%), blocked AF or AF with bradycardia (17.0%). Bundle branch block (5.4%) was the least common indication.

Most implanted leads were bipolar, both in the right atrium and right ventricle, and also, following the trend described above, in the coronary sinus (95.1% in 2016). The information submitted to the Spanish Pacemaker Registry does not include the use of quadripolar left ventricular pacing leads through the coronary sinus. This technique makes it possible to choose, among multiple electronic configurations, the one with the best electrical behavior and without phrenic pacing. Neither is information available on the use of multipoint pacing in cardiac resynchronization, which is a novel therapy with initial benefits in acute hemodynamics and left ventricular asynchrony, with medium-term clinical benefit.21 Most leads were for active fixation systems (82.9%), both in the atrium and ventricle. Unlike previous years, a similar percentage was used in patients older or younger than 80 years, probably because of their demonstrated benefit in stability, alternative implant sites, optimal electrical behavior, and low complication rates. The use of MRI-compatible leads was still low (16.1%). This percentage may be due to the low implant rate of MRI-compatible generators (although these data are not included in EPPIC), which are high-end devices with higher costs. The use of these leads was even lower in older patients (12.9% in patients older than 80 years). Because of the progressive population aging and the increasing use of MRI, it is advisable to greatly increase the use of systems compatible with this radiological technique.

Of note was the growing application of home monitoring systems, with a significant increase compared with that of previous years (from 5% to 20% in conventional pacemakers and from 15.9% to 65% in CRT-P devices). This is a clearly positive trend, as it is a safe, cost-effective strategy that enables the early detection and response to events.

For the second consecutive year, the Spanish Pacemaker Registry included data on leadless pacemaker implantation. During 2016, the number of such devices implanted (200) was twice that of the previous year.15 The number of autonomous communities implanting these devices also increased from 9 to 13. Although the cost of these pacemakers continues to be higher than that of a conventional VVI/R pacemaker, the long-term benefits of the absence of cables in the vascular space, the increased availability of this technology, and the scientific evidence corroborating its effectiveness and mid-term safety may explain the progressive increase in the number of implants.22,23

As in previous years, the most common preoperative electrocardiographic abnormality was AVB (mainly third-degree AVB). In AVB, the most frequently used pacing mode continued to be atrial synchronous pacing (74.9%). The use of DDD/R pacing slightly decreased compared with that of the previous year (60.6%), and it is noteworthy that the use of VVI/R and VDD/R mode remained stable (23.8% and 14.8%, respectively). In AVB, age continued to be a determining factor in pacing-mode selection. Most patients aged 80 years or younger with AVB received DDD/R pacing, whereas in those older than 80 years the percentage of single-chamber pacing continued to be high, although it slightly decreased compared with the previous year (37.8%). Pacing in VDD/R mode to maintain AV synchrony was used more frequently in patients older than 80 years than in the younger group (19.5% vs 11.8%) and its use slightly increased slightly compared with that of the previous year.

In SSS, atrial-based pacing continued to be the most commonly used mode, with a predominance of DDD/R mode (69.1%), as recommended by current clinical practice guidelines. However, VVI/R mode continued to be used in 26.7% of SSS patients, representing a change in the downward trend observed in recent years. In SSS, age also continued to influence pacing-mode selection. Single-chamber VVI/R pacing was more common in patients older than 80 years (39%) and in bradycardia-tachycardia syndrome (53.5%), possibly due to the risk of going into permanent AF in the near future or because of the erroneous inclusion of patients with permanent slow-fast AF in this group. The current guidelines recommend pacing with DDD/R mode in SSS, mainly because it decreases the incidence of AF and stroke and lowers the risk of pacemaker syndrome, which can adversely affect patients’ quality of life. Pacing in AAI/R mode continued to decrease, probably due to increased compliance with the current clinical practice guidelines based on the results of the DANPACE study,24 and to the disadvantages of this pacing mode (0.6% to 1.9% of patients with SSS develop AVB each year). In atrial tachyarrhythmia with slow ventricular response, VVI/R pacing was the most commonly used mode.

In intraventricular conduction defects, DDD/R (52.4%) was the most frequently used mode, followed by VVI/R (29.2%). In patients older than 80 years, for the first time, VVI/R mode was used more often than DDD/R mode (47.5% vs 35.7%). In contrast, most patients aged 80 years or younger received DDD/R pacing, although the percentage of single-chamber pacing doubled compared with that of the previous year (16.3%). VDD/R mode was used less frequently, and its deployment in patients older than 80 years was twice that of the younger age group. Low-energy CRT pacing continued to be relevant in this patient subgroup (9.6% of implants), but its use decreased compared with that of the previous year. In patients with intraventricular conduction defects, age was once again an important factor in the use of CRT-P (≤ 80 years, 12.9%; > 80 years, 5.6%).

CONCLUSIONS

The use of conventional pacemakers and CRT-P has continued to increase, although the average number of such implantations remains below that of other European countries. Age was the main factor affecting the choice of pacing mode, which was inappropriate in up to 20% of patients with AVB and SSS. Leadless pacing has become established, and its use significantly increased in 2016 with a greater number of implantation centers. There was a significant increase in the percentage of remote monitoring devices.

CONFLICTS OF INTEREST

None declared.

References
[1]
R. Coma Samartín.
Estado actual de la estimulación cardiaca definitiva en España. Informe del Banco Nacional de Datos de Marcapasos.
Rev Esp Cardiol., 50 (1997), pp. 760-765
[2]
R. Coma Samartín.
Banco Nacional de Datos de Marcapasos. Informe año 2002.
Cuadernos Técnicos de Estimulación Cardiaca., 10 (2004), pp. 37-42
[3]
R. Coma Samartín.
Registro Español de Marcapasos. II Informe oficial de la Sección de Estimulación Cardiaca de la Sociedad Española de Cardiología (1994-2003).
Rev Esp Cardiol., 57 (2004), pp. 1205-1212
[4]
R. Coma Samartín, B. Martínez Noriega, P. Gómez Pérez.
Informe del Banco Nacional de Datos de Marcapasos. Año 2004.
Cuadernos Técnicos de Estimulación Cardiaca., 14 (2006), pp. 25-32
[5]
R. Coma Samartín, R. García Calabozo, J. Martínez Ferrer, M.J. Sancho-Tello Carranza, F. Ruiz Mateas.
Registro Español de Marcapasos. III Informe Oficial de la Sección de Estimulación Cardiaca de la Sociedad Española de Cardiología (2005).
Rev Esp Cardiol., 59 (2006), pp. 1303-1313
[6]
R. Coma Samartín, J. Martínez Ferrer, M.J. Sancho-Tello de Carranza, F. Ruiz Mateas, J. Leal del Ojo González.
Registro Español de Marcapasos. IV Informe Oficial de la Sección de Estimulación Cardiaca de la Sociedad Española de Cardiología (2006).
Rev Esp Cardiol., 60 (2007), pp. 1302-1313
[7]
R. Coma Samartín, J. Martínez Ferrer, M.J. Sancho-Tello de Carranza, F. Ruiz Mateas, J. Leal del Ojo González.
Registro Español de Marcapasos. V Informe Oficial de la Sección de Estimulación Cardiaca de la Sociedad Española de Cardiología (2007).
Rev Esp Cardiol., 61 (2008), pp. 1315-1328
[8]
R. Coma Samartín, J. Martínez Ferrer, M.J. Sancho-Tello de Carranza, F. Ruiz Mateas, J. Leal del Ojo González.
Registro Español de Marcapasos. VI Informe Oficial de la Sección de Estimulación Cardiaca de la Sociedad Española de Cardiología (2008).
Rev Esp Cardiol., 62 (2009), pp. 1450-1463
[9]
R. Coma Samartín, M.J. Sancho-Tello de Carranza, F. Ruiz Mateas, J. Leal del Ojo González, M.L. Fidalgo Andrés.
Registro Español de Marcapasos. VII Informe Oficial de la Sección de Estimulación Cardiaca de la Sociedad Española de Cardiología (2009).
Rev Esp Cardiol., 63 (2010), pp. 1452-1467
[10]
R. Coma Samartín, M.J. Sancho-Tello de Carranza, F. Ruiz Mateas, J. Leal del Ojo González, M.L. Fidalgo Andrés.
Registro Español de Marcapasos. VIII Informe Oficial de la Sección de Estimulación Cardiaca de la Sociedad Española de Cardiología (2010).
Rev Esp Cardiol., 64 (2011), pp. 1154-1167
[11]
R. Coma Samartín, M.J. Sancho-Tello de Carranza, F. Ruiz Mateas, J. Leal del Ojo González, M.L. Fidalgo Andrés.
Registro Español de Marcapasos. IX Informe Oficial de la Sección de Estimulación Cardiaca de la Sociedad Española de Cardiología (2011).
Rev Esp Cardiol., 65 (2012), pp. 1117-1132
[12]
R. Coma Samartín, F. Ruiz Mateas, M.L. Fidalgo Andrés, J. Leal del Ojo González, L. Pérez Álvarez.
Registro Español de Marcapasos. X Informe Oficial de la Sección de Estimulación Cardiaca de la Sociedad Española de Cardiología (2012).
Rev Esp Cardiol., 66 (2013), pp. 959-972
[13]
R. Coma Samartín, O. Cano Pérez, M. Pombo Jiménez.
Registro Español de Marcapasos. XI Informe Oficial de la Sección de Estimulación Cardiaca de la Sociedad Española de Cardiología (2013).
Rev Esp Cardiol., 67 (2014), pp. 1024-1038
[14]
O. Cano Pérez, M. Pombo Jiménez, R. Coma Samartín.
Registro Español de Marcapasos. XII Informe Oficial de la Sección de Estimulación Cardiaca de la Sociedad Española de Cardiología (2014).
Rev Esp Cardiol., 68 (2015), pp. 1138-1153
[15]
M. Pombo Jiménez, O. Cano Pérez, M.L. Fidalgo Andrés, D. Lorente Carreño, R. Coma Samartín.
Registro Español de Marcapasos. XIII Informe Oficial de la Sección de Estimulación Cardiaca de la Sociedad Española de Cardiología (2015).
Rev Esp Cardiol., 69 (2016), pp. 1190-1203
[16]
M.J. Raatikainen, D.O. Arnar, B.E. Merkely, A.J. Camm, G. Hindriks.
Access to and clinical use of cardiac implantable electronic devices and interventional electrophysiological procedures in the European Society of Cardiology Countries: 2016 Report from the European Heart Rhythm Association.
Europace, 18 Suppl 3 (2016), pp. iii1-iii79
[17]
Instituto Nacional de Estadística [Accessed 1 Jul 2017]. Available at: http://www.ine.es
[18]
Eucomed. Medical Technology Statistics for Cardiac Rhythm Management products, 2012-2016 [Accessed 1 Jul 2017]. Available at: http://www.medtecheurope.org
[19]
M. Brignole, A. Auricchio, G. Baron-Esquivias, et al.
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.
Eur Heart J., 34 (2013), pp. 2281-2329
[20]
A.R. Epstein, J.P. DiMarco, A. Kenneth, et al.
2012 ACCF/AHA/HRS focused update incorporated into the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities.
Circulation., 127 (2013), pp. e283-e352
[21]
J. Osca, P. Alonso, O. Cano, et al.
The use of multisite left ventricular pacing via quadripolar lead improves acute haemodynamics and mechanical dyssynchrony assessed by radial strain speckle tracking: initial results.
Europace., 18 (2016), pp. 560-567
[22]
J.L. Martínez-Sande, J. García-Seara, M. Rodríguez-Mañero, et al.
Marcapasos transcatéter sin cables Micra. Resultados del implante y seguimiento a medio plazo en un centro.
Rev Esp Cardiol., 70 (2017), pp. 275-281
[23]
P.R. Roberts, N. Clementy, F. Al Samadi, et al.
A leadless pacemaker in the real-world setting: The Micra Transcatheter Pacing System Post-Approval Registry.
[24]
J.C. Nielsen, P.E. Thomsen, S. Højberg, et al.
DANPACE Investigators. A comparison of single-lead atrial pacing with dualchamber pacing in sick sinus syndrome.
Eur Heart J, 32 (2011), pp. 686-696
Copyright © 2017. Sociedad Española de Cardiología
Idiomas
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

View newsletter history
Article options
Tools